Global T-Cell Lymphoma Market

Description

Market Overview

The T-Cell Lymphoma Market reached US$ 1,485.2 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 2,787.8 million by 2030. The T-cell lymphoma market is expected to exhibit a CAGR of 8.4% during the forecast period (2023-2030).

T-cell lymphoma is classified into two types: peripheral T-cell lymphoma and T-cell lymphoblastic lymphoma. T-cell lymphoma can be treated with chemotherapy, radiotherapy, immunotherapy, antiviral medication, stem cell transplantation, and other therapies.

The growth of the T-cell lymphoma market is also attributed to the rise in lymphoma cancer incidence due to radiation, an increase in the number of T-cell lymphoma-specific therapies, and the risk of lymphoma due to autoimmune disorders.

Market Dynamics

Increase in Prevalence of Cancer Worldwide

The increase in the prevalence rate of cancer is one of the drivers that affect the T Cell lymphoma market opportunities. Another factor is increasing investment in healthcare infrastructure and the rising geriatric population that leads to the expansion of the T-cell lymphoma market.

According to WHO, cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. Each year, approximately 400,000 children develop cancer. The most common cancers vary between countries.

High Cost and Long Duration of Treatment

Treatment for T-cell lymphoma is very expensive because of its unique mechanism of action and the collections and manufacturing processes also add to the total costs. The high cost of the treatment also varies from patient to patient according to the level of disease and level of treatment required as per the patient standards.

COVID-19 Impact Analysis

The COVID-19 pandemic had a negative impact on the global T-cell lymphoma market trend over the projection period, owing to disruptions in cancer treatment services and the halt of clinical trials for cancer therapy.

Due to the COVID-19 epidemic, patients with cutaneous lymphomas were at an increased risk of missing receiving crucial diagnostic tests and treatments, either because hospitals were difficult for them to access or because of a lack of available healthcare resources.

Segment Analysis

The Chemotherapy Segment will Dominate the Market in the Forecast Period with around 40.8% Market Share

Chemotherapy is a common treatment for T-cell lymphoma because it inhibits and slows the proliferation of cancer cells. In addition to surgery and radiation therapy, chemotherapy can affect the entire body. These treatments can destroy or eliminate cancer cells in a specific area of the body.

Also, a combination chemotherapy regimen, such as CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), CHOEP (etoposide, vincristine, doxorubicin, cyclophosphamide, and prednisone), or other multidrug regimens, is frequently used for treatment.

Geographical Analysis

North America is the Dominating Region During The Forecast Period Accounting For 42.4% In The Overall Market

The global T-cell lymphoma market is large in the North American region due to the high number of cases of T-cell lymphoma, the presence of strong rivals, and increased research in the North American region. Also, T-cell lymphomas are a subtype of Non-Hodgkin lymphoma and a rise in Non-Hodgkin lymphoma cases would likely increase the demand for new treatment options, assisting the market's growth.

Competitive Landscape

The major global players include: Johnson & Johnson, Novartis AG, Bristol Myers Squibb Company, Merck & Co Inc, F.Hoffmann La Roche Ltd, Acrotech Biopharma, GlaxoSmithKline Plc, and Spectrum Pharmaceuticals.

Why Purchase the Report?
To visualize the global T-cell lymphoma market segmentation based on the type, end user and region, as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of global T-cell lymphoma market level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as Excel consisting of key products of all the major players.

The global T-cell lymphoma market report would provide approximately 92 tables, 108 figures and 195 pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

Product Code: PH1486

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Type
3.2. Snippet by Treatment
3.3. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Increase in the prevalence of cancer worldwide
- 4.1.2. Restraints
  - 4.1.2.1. High cost and long duration of treatment
- 4.1.3. Opportunity
  - 4.1.3.1. Rise in the investments and research funding of T-cell lymphoma market
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID-19
- 6.1.2. Scenario During COVID-19
- 6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. By Drug Class

7.1. Peripheral T Cell Lymphoma
7.2. Cutaneous T Cell Lymphoma
7.3. Anaplastic Large Cell Lymphoma
7.4. Others

8. By Treatment

8.1. Radiotherapy
8.2. Chemotherapy
8.3. Targeted Therapy
8.4. Surgery
8.5. Stem Cell Transplantation
8.6. Others

9. By Region

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 9.1.2. Market Attractiveness Index, By Region
9.2. North America
- 9.2.1. Introduction
- 9.2.2. Key Region-Specific Dynamics
- 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
- 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.2.5.1.1. The U.S.
  - 9.2.5.1.2. Canada
  - 9.2.5.1.3. Mexico
9.3. Europe
- 9.3.1. Introduction
- 9.3.2. Key Region-Specific Dynamics
- 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
- 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.3.5.1.1. Germany
  - 9.3.5.1.2. The UK
  - 9.3.5.1.3. France
  - 9.3.5.1.4. Italy
  - 9.3.5.1.5. Spain
  - 9.3.5.1.6. Rest of Europe
9.4. South America
- 9.4.1. Introduction
- 9.4.2. Key Region-Specific Dynamics
- 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
- 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.4.5.1.1. Brazil
  - 9.4.5.1.2. Argentina
  - 9.4.5.1.3. Rest of South America
9.5. Asia-Pacific
- 9.5.1. Introduction
- 9.5.2. Key Region-Specific Dynamics
- 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
- 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.5.5.1.1. China
  - 9.5.5.1.2. India
  - 9.5.5.1.3. Japan
  - 9.5.5.1.4. Australia
  - 9.5.5.1.5. Rest of Asia-Pacific
9.6. Middle East and Africa
- 9.6.1. Introduction
- 9.6.2. Key Region-Specific Dynamics
- 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
- 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

10. Competitive Landscape

10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis

11. Company Profiles

11.1. Johnson & Johnson
11.2. Novartis AG
11.3. Bristol Myers Squibb Company
11.4. Merck & Co Inc
11.5. F.Hoffmann La Roche Ltd
11.6. Acrotech Biopharma
11.7. GlaxoSmithKline Plc
11.8. Spectrum Pharmaceuticals

LIST NOT EXHAUSTIVE

12. Appendix

12.1. About Us and Services
12.2. Contact Us

Global T-Cell Lymphoma Market - 2023-2030